Engineering multilevel cell sheet-derived blood vessels

Patent metadata

Field	Value
Publication number	US-2019134274-A1
Application number	US-201816180359-A
Country	US
Kind code	A1
Filing date	Nov 5, 2018
Priority date	Nov 9, 2017
Publication date	May 9, 2019
Grant date	—

Abstract

Engineered multilevel cell sheet-derived blood vessels and methods of preparing and using them are disclosed. Blood vessels are generated by wrapping cell sheets around a rod-like device, such as an angiocath needle, to form a tube, which is stabilized with a cyanoacrylate membrane or fibrin glue followed by endothelialization. Such engineered blood vessels can be implanted in tissue and used in vascular surgery as vascular bypass or interposition grafts as well as for vascularization and perfusion of tissue or organs prior to transplant.

First claim

What is claimed is:

1 . A method of making a tissue-engineered blood vessel comprising:
a) culturing fibroblasts and smooth muscle cells to form one or more confluent cell sheets; b) wrapping said one or more cell sheets around a rod-like device to form a tube; c) stabilizing the tube formed from the cell sheets with a cyanoacrylate membrane or fibrin glue; d) endothelialization of the tube formed from the cell sheets by culturing with endothelial cells; and e) removing the rod-like device to form the tissue-engineered blood vessel.

2 . The method of claim 1 , wherein the fibroblasts and smooth muscle cells are from a human subject.

3 . The method of claim 1 , wherein the endothelial cells are human umbilical vein endothelial cells.

4 . The method of claim 1 , wherein the diameter of the rod-like device is less than or equal to 1 mm.

5 . The method of claim 1 , wherein the rod-like device is a mandrel or needle.

6 . The method of claim 5 , wherein the needle is an angiocath needle.

7 . The method of claim 5 , wherein the needle has a gauge of at least 11, at least 16, at least 18, at least 20, at least 22, or at least 22.5.

8 . The method of claim 7 , wherein the needle has a gauge ranging from 11 to 24.

9 . The method of claim 8 , wherein the needle has a gauge of 22.5.

10 . The method of claim 1 , wherein at least 4, 5, 6, 7, 8, 9, 10, 11, or 12 cell sheets are wrapped around the rod-like device to form the tube.

11 . The method of claim 1 , wherein 5 to 10 cell sheets are wrapped around the rod-like device to form the tube.

12 . A tissue-engineered blood vessel produced by the method of claim 1 .

13 . The tissue-engineered blood vessel of claim 12 , wherein the diameter of the tissue-engineered blood vessel is less than or equal to 1 mm.

14 . A method of treating a subject fora cardiovascular disease or disorder, the method comprising implanting the tissue-engineered blood vessel of claim 12 in the subject.

15 . The method of claim 14 , further comprising linking the tissue-engineered blood vessel to a vein or artery by surgical anastomosis.

16 . The method of claim 14 , wherein the tissue-engineered blood vessel is used in a vascular bypass or interposition graft.

17 . The method of claim 14 , wherein the cardiovascular disease or disorder is selected from the group consisting of coronary artery disease, ischemic heart disease, ischemic stroke, peripheral artery disease, cerebrovascular disease, atherosclerosis, arteriosclerosis, angina, myocardial infarction, and embolism.

18 . The method of claim 14 , wherein the fibroblasts, smooth muscle cells, or endothelial cells are autologous, xenogeneic, or allogeneic.

19 . A method of vascularizing a tissue or organ for transplant, the method comprising implanting the tissue-engineered blood vessel of claim 12 in the tissue or organ.

20 . The method of claim 19 , wherein the tissue is heart muscle.

21 . The method of claim 19 , wherein said implanting is performed prior to or after transplant of the tissue or organ into a subject.

22 . The method of claim 19 , further comprising cultivation of the tissue around the tissue-engineered blood vessel.

23 . The method of claim 19 , further comprising perfusing the vascularized tissue wherein blood flows through the tissue-engineered blood vessel.

24 . The method of claim 19 , further comprising transplanting the vascularized tissue or organ into a subject.

25 . The method of claim 19 , further comprising linking the tissue-engineered blood vessel to a vein or artery by surgical anastomosis.

26 . A method of engineering a perfused heart muscle tissue graft, the method comprising:
a) producing a tissue-engineered blood vessel according to the method of claim 1 ; b) co-culturing the tissue-engineered blood vessel with cardiomyocytes to produce a vascularized heart muscle tissue graft, wherein vessel sprouting from the tissue-engineered blood vessel produces a vascular network within the heart muscle tissue graft; and c) perfusing the cardiomyocyte tissue graft, wherein blood flows through the tissue-engineered blood vessel and the vascular network within the heart muscle tissue graft.

27 . The method of claim 26 , wherein the cardiomyocytes are autologous, xenogeneic, or allogeneic.

28 . The method of claim 26 , wherein the cardiomyocytes are human induced cardiomyocytes.

Assignees

• Univ Leland Stanford Junior

Inventors

• Von Bornstaedt Daniel
• Woo Y Joseph
• Wang Hanjay

Classifications

• A61L27/507 Primary

  for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062) · CPC title

• A61L2430/40

  Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking · CPC title

• A61L27/3808

  Endothelial cells · CPC title

• A61L27/3895

  using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions · CPC title

• A61L27/3826

  Muscle cells, e.g. smooth muscle cells · CPC title